%0 Journal Article
%T Establishment and characterization of a sustained delayed-type hypersensitivity model with arthritic manifestations in C57BL/6J mice
%A Sara M Atkinson
%A Pernille A Usher
%A Peter H Kvist
%A Helle Markholst
%A Claus Haase
%A Anneline Nansen
%J Arthritis Research & Therapy
%D 2012
%I BioMed Central
%R 10.1186/ar3867
%X DTH-arthritis was induced by eliciting a classical DTH reaction in one paw with methylated bovine serum albumin (mBSA), with the modification that a cocktail of type II collagen monoclonal antibodies was administered between the immunisation and challenge steps. Involved cell subsets and inflammatory mediators were analysed, and tissue sections evaluated histopathologically. Disease was treated prophylactically and therapeutically with compounds used in the treatment of RA.We demonstrate that DTH-arthritis could be induced in C57BL/6 mice with paw swelling lasting for at least 28 days and that disease induction was dependent on CD4+ cells. We show that macrophages and neutrophils were heavily involved in the observed pathology and that a clear profile of inflammatory mediators associated with these cell subsets was induced locally. In addition, inflammatory markers were observed systemically. Furthermore, we demonstrate that disease could be both prevented and treated.Our findings indicate that DTH-arthritis shares features with both collagen-induced arthritis (CIA) and human RA. DTH-arthritis is dependent on CD4+ cells for induction and can be successfully treated with TNF¦Á-blocking biologics and dexamethasone. On the basis of our findings we believe that the DTH-arthritis model could hold potential in the preclinical screening of novel drugs targeting RA. The model is highly reproducible and has a high incidence rate with synchronised onset and progression, which strengthens its potential.Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by severe synovitis leading to the destruction of articular cartilage and bone erosion. This ultimately results in joint destruction and severe disability and decreased quality of life for the affected patients [1]. Although the precise etiology and pathogenesis of RA remain unknown, several therapeutic advances have been made in recent years, most notably through blockade of tumor necrosis factor
%U http://arthritis-research.com/content/14/3/R134